市場調査レポート
商品コード
1462280
AMG0001市場:市場規模、予測、新たな洞察-2032年AMG0001 Market Size, Forecast, and Emerging Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
AMG0001市場:市場規模、予測、新たな洞察-2032年 |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
AMG0001(COLLATEGENE)は再生医療製品であり、その主成分はHGFのcDNAを含む5181塩基対のHGF遺伝子をコードするプラスミドDNA(Beperminogene Perplasmid)です。閉塞性動脈硬化症(ASO)またはバージャー病のCLIを治療することを目的としています。医薬品と同様に薬理学的治療効果を期待して開発されました。コラテジェンを虚血部位近傍の筋肉に注射することで、HGF産生・放出による血管新生を誘導し、血管数と血流を増加させることで虚血肢の状態を改善することが期待されます。ASOやバージャー病患者における重症四肢虚血の治療薬と考えられています。
今後数年間で、末梢動脈疾患(PAD)の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、AMG0001の優位性に影響を与える可能性のある機会を模索しています。PADに対する他の新興製品がAMG0001と厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。
当レポートでは、主要6ヶ国における末梢動脈疾患(PAD)のAMG0001市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。
"AMG0001 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about AMG0001 for Peripheral Artery Disease (PAD) in the six major markets. A detailed picture of the AMG0001 for PAD in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the AMG0001 for PAD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AMG0001 market forecast analysis for PAD in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PAD.
AMG0001 (COLLATEGENE) is a regenerative medical product, and its main component is a plasmid DNA encoding the HGF gene of 5181 base pairs, containing the cDNA for HGF (Beperminogene Perplasmid). It is intended to treat the CLI of arteriosclerosis obliterans (ASO) or Buerger's disease. It was developed with an expectation of its pharmacological therapeutic effects, as with pharmaceuticals. COLLATEGENE administered by injection into muscles near the ischemic focus is expected to induce angiogenesis through HGF production/release and improve the ischemic state of the limb by increasing the number of blood vessels and blood flow. It is considered therapeutic in treating critical limb ischemia in patients with ASO or Buerger's disease.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
AMG0001 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of AMG0001 for Peripheral Artery Disease (PAD) in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2026 to 2032.
The report provides the clinical trials information of AMG0001 for PAD covering trial interventions, trial conditions, trial status, start and completion dates.